Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Matthew P. Goetz, MD, Mayo Clinic, Rochester, Minnesota, describes how resistance to endocrine therapy often develops in ER-positive breast cancer through emergence of ESR1 mutations, which occur in…
In this podcast, hosts Drs. Rahul and Rohit Gosain, and Jame Abraham, MD, Cleveland Clinic, highlight findings from the EMBER-3 study comparing imlunestrant alone versus imlunestrant combined with…
In this video, Virginia Kaklamani, MD, UT Health San Antonio, Texas, reviews the results of the EMBER-3 Phase 3 trial of imlunestrant, an oral SERD, in patients with…
Suzanne A. W. Fuqua, PhD, Baylor College of Medicine, explains that while the role of ESR1 mutations in primary breast cancer remains controversial, earlier studies have reported specific…
On September 25, 2025, the FDA approved Inluriyo (imlunestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This video explores the breakthrough, including clinical data from the…
In this video, Aditya Bardia, MD, MPH, Massachusetts General Hospital, and Donald McDonnell, PhD, Duke University, explain that ESR1 mutations often arise in metastatic, hormone-receptor positive breast cancers…
In an interview that took place at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, Timothy Yap, MBBS, PhD, medical oncologist, The University of Texas…
